ALLERGOL. ET IMMUNOPATHOL., 1998;26(4):201
NEWS
PATIENT ACCEPTANCE AND SHORTENED CYCLES PAINT OPTIMISTIC FUTURE FOR THERAPEUTIC VACCINE MANUFACTURERS
Mountain View, California. Viruses are difficult to treat because they mutate rendering initially effective drugs useless against new viral strains. By targeting only the highly conserved areas of viral protein, protein-based or deoxyribonucleic acid (DNA) therapeutic vaccines hope to become the treatment breakthrough patients have been waiting for.
World Therapeutic Vaccines Market. Studies the market potential for therapeutic vaccines treating AISD, cancer and autoimmune diseases. The study spotlights each disease individually to give an in-depth examination of the discovery, research and developmental phases of market participants.
The significant acceleration of drug approval by the FDA is very encouraging to manufacturers in all markets. Through the Prescription Drug User Fee Act (PDUFA), the FDA collects fees from drug companies to increase its resources and shorten approval time. The Biotechnology Industry Organization (BIO) is working with the FDA to formulate PDUFA II that would mean a further reduction from 27 to 15 months.
Physician and patient acceptance toward therapeutic vaccines is high, especially for life-threatening illnesses such as AIDS and cancer. Once this perception is confirmed by clinical trial results, the market for therapeutic vaccines may expand tremendously as it begins to include patients who previously would not have considered these alternative treatments.
"In terms of patient populations, the market opportunity is large, but the types of treatments available on the market will help in defining acceptance by patients", said Archana Asthana, medical analyst at Frost & Sullivan.
"Often, therapies are not available to the average patient, or are highly toxic if available. New products could meet with great success, if they can be effective, accessible and nontoxic".
The first therapeutic vaccine is scheduled to enter the market in 1998 to treat melanoma cancer. Cancer has received encouragement through clinical trials from the targeted population, and the long term effects on survival and recurrence are eagerly awaited. Therapeutic vaccines for breast, stomach and ovarian cancer are also expected to become available shortly after the turn of the century.
The positive clinical results from combination triple drug therapy originally caused a stir among AIDS patients, but this enthusiasm has been tempered by the eventual drug resistance found in some patients. Researchers are hoping that The Immune Response Corporation''s therapeutic vaccine Remune, slated for a 1999 release, will provide better long term results.
Critical phases of the research included: identification of industry challenges, market engineering measurements, strategic recommendations, planning and market monitoring. All of the vital elements of this system help the market participants navigate successfully through the therapeutic vaccine markets (www.frost.com).
| Total Therapeutic Vaccines Market: | |||
| Revenue Forecasts (World), 1997-2003 | |||
Revenue | |||
| Rate | Revenues | Growth | |
| Year | ($ Million) | (%) | |
| 1997 | 0.0 | | |
| 1998 | 2.1 | | |
| 1999 | 79.4 | 3,679.5 | |
| 2000 | 213.5 | 169.0 | |
| 2001 | 566.2 | 165.1 | |
| 2002 | 721.5 | 27.4 | |
| 2003 | 926.8 | 28.4 | |
| Compound Annual Growth Rate (1998-2003): 213.3% Source: Frost & Sullivan, Report 5349. | |||
